The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ALS in the EU.

CHMP upheld earlier opinions that Translarna is not of significant benefit to DMD due to nonsense mutations; European ...

In addition, the FDA awarded an Orphan Products Development grant to support the evaluation of HyBryteTM for expanded treatment in patients with early-stage CTCL, including in the home use setting.

SHELTON, CT / ACCESSWIRE /2, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R.

Sangamo Therapeutics, Inc. , a genomic medicine company, today announced the outcome of a recent successful interaction with the U.S. FDA, providing a clear regulatory pathway to Accelerated Approval ...